towards improved death receptor targeted therapy for ... - TI Pharma

Chapter 5
Reference List
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5):277‐
300.
2. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for
cancer therapy. Cytokine Growth Factor Rev 2003; 14(3‐4):337‐348.
3. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008; 263(1):14‐25.
4. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene
2010; 29(34):4752‐4765.
5. Forero‐Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C et al. Phase I trial of
weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death
receptor 5 (DR5). Cancer Biother Radiopharm 2010; 25(1):13‐19.
6. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W et al. Phase 2 study of
mapatumumab, a fully human agonistic monoclonal antibody which targets and activates
the TRAIL receptor‐1, in patients with advanced non‐small cell lung cancer. Lung Cancer
2008; 61(1):82‐90.
7. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L et al. A first‐in‐human study
of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010;
16(23):5883‐5891.
8. Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor
targeting therapies for non‐small cell lung cancer: current status and perspectives. Drug
Resist Updat 2010; 13(1‐2):2‐15.
9. Eid MA, Lewis RW, Abdel‐Mageed AB, Kumar MV. Reduced response of prostate cancer
cells to TRAIL is modulated by NFkappaB‐mediated inhibition of caspases and Bid
activation. Int J Oncol 2002; 21(1):111‐117.
10. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 3'‐kinase/PTEN/Akt kinase
pathway in tumor necrosis factor‐related apoptosis‐inducing ligand‐induced apoptosis in
non‐small cell lung cancer cells. Cancer Res 2002; 62(17):4929‐4937.
11. Song JH, Tse MC, Bellail A, Phuphanich S, Khuri F, Kneteman NM et al. Lipid rafts and
nonrafts mediate tumor necrosis factor related apoptosis‐inducing ligand induced
apoptotic and non‐apoptotic signals in non small cell lung carcinoma cells. Cancer Res
2007; 67(14):6946‐6955.
12. Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG et al. Src
and ADAM‐17‐mediated shedding of transforming growth factor‐alpha is a mechanism of
acute resistance to TRAIL. Cancer Res 2008; 68(20):8312‐8321.
13. Altieri DC. Coupling apoptosis resistance to the cellular stress response: the IAP‐Hsp90
connection in cancer. Cell Cycle 2004; 3(3):255‐256.
14. Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ et al. Integration
of gene dosage and gene expression in non‐small cell lung cancer, identification of HSP90
as potential target. PLoS One 2008; 3(3):e0001722.
15. Zuehlke A, Johnson JL. Hsp90 and co‐chaperones twist the functions of diverse client
proteins. Biopolymers 2010; 93(3):211‐217.
16. Nguyen DM, Chen A, Mixon A, Schrump DS. Sequence‐dependent enhancement of
paclitaxel toxicity in non‐small cell lung cancer by 17‐allylamino 17‐
demethoxygeldanamycin. J Thorac Cardiovasc Surg 1999; 118(5):908‐915.
17. Bijnsdorp IV, Kruyt FA, Gokoel S, Fukushima M, Peters GJ. Synergistic interaction between
trifluorothymidine and docetaxel is sequence dependent. Cancer Sci 2008; 99(11):2302‐
2308.
18. Wang X, Ju W, Renouard J, Aden J, Belinsky SA, Lin Y. 17‐allylamino‐17‐
demethoxygeldanamycin synergistically potentiates tumor necrosis factor‐induced lung
cancer cell death by blocking the nuclear factor‐kappaB pathway. Cancer Res 2006;
66(2):1089‐1095.
‐ 96 ‐